European principles of inhibitor management in patients with haemophilia: implications of new treatment options

• Authors: HERMANS C.; GIANGRANDE P. L. F.; O MAHONY B.; DE KLEIJN P.; BEDFORD M.; BATOROVA A.; BLATNÝ Jan; JANSONE K.
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: Orphanet Journal of Rare Diseases
• MU Faculty or unit: Faculty of Medicine
• Web: https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
• Doi: http://dx.doi.org/10.1186/s13023-020-01511-8
• Keywords: Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance
• Description: In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).